LEADER 04367nam 22007335 450 001 9910410043003321 005 20200705112705.0 010 $a3-030-42443-X 024 7 $a10.1007/978-3-030-42443-5 035 $a(CKB)4100000011254607 035 $a(MiAaPQ)EBC6202740 035 $a(DE-He213)978-3-030-42443-5 035 $a(PPN)24839570X 035 $a(EXLCZ)994100000011254607 100 $a20200518d2020 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCoronary Artery Disease and The Evolution of Angioplasty Devices /$fby Martin W. King, Tushar Bambharoliya, Harshini Ramakrishna, Fan Zhang 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (78 pages) 225 1 $aSpringerBriefs in Materials,$x2192-1091 311 $a3-030-42442-1 320 $aIncludes bibliographical references and index. 327 $aChapter1. Epidemiology and Risk Factors -- Chapter2. Definitions and Basic Mechanism of Coronary Artery Disease (CAD) -- Chapter3. Coronary Microvascular Dysfunction (CMD) -- Chapter4. Diagnosis of Coronary Artery Disease -- Chapter5. Treatment of Coronary Artery Disease -- Chapter6. Evolution of Angioplasty. 330 $aIn this concise but authoritative book, the authors take the reader through the epidemiology, risk factors and the basic mechanism of coronary artery disease. In addition, they explain how coronary microvascular dysfunction can lead to angina, even after successful angioplasty following a heart attack. The methods for diagnosis and the options for treatment are explained, ending with a discussion of the evolution of coronary angioplasty from balloon catheters to novel, fully resorbable polymeric drug eluting stents. Enclosed is a list of currently available commercial devices, as well as a listing of experimental products under research and development, so that readers can appreciate the serious nature of this disease and have an understanding of how the medical device sector is attempting to address this major healthcare problem. Globally in 2010, ischemic heart disease was the cause of 13.3% of all deaths. In the US alone, the direct medical costs from coronary artery disease and stroke are currently estimated to be $126 billion per year, and are expected to rise to $309 billion by 2035. 410 0$aSpringerBriefs in Materials,$x2192-1091 606 $aBiomaterials 606 $aBiomedical engineering 606 $aCardiology 606 $aBlood-vessels$xSurgery 606 $aHeart$xSurgery 606 $aBiomaterials$3https://scigraph.springernature.com/ontologies/product-market-codes/Z13000 606 $aBiomedical Engineering and Bioengineering$3https://scigraph.springernature.com/ontologies/product-market-codes/T2700X 606 $aBiomedical Engineering/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/B24000 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aVascular Surgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59133 606 $aCardiac Surgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59028 615 0$aBiomaterials. 615 0$aBiomedical engineering. 615 0$aCardiology. 615 0$aBlood-vessels$xSurgery. 615 0$aHeart$xSurgery. 615 14$aBiomaterials. 615 24$aBiomedical Engineering and Bioengineering. 615 24$aBiomedical Engineering/Biotechnology. 615 24$aCardiology. 615 24$aVascular Surgery. 615 24$aCardiac Surgery. 676 $a616.123 700 $aKing$b Martin W$4aut$4http://id.loc.gov/vocabulary/relators/aut$01071362 702 $aBambharoliya$b Tushar$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aRamakrishna$b Harshini$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aZhang$b Fan$4aut$4http://id.loc.gov/vocabulary/relators/aut 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910410043003321 996 $aCoronary Artery Disease and The Evolution of Angioplasty Devices$92566904 997 $aUNINA